Investor Presentaiton
The global medical market's demand for life
science products and services keeps attracting
investment throughout the R&D, clinical and
manufacturing phases.
Medical outsourcing has been on the rise in
recent years. In 2021, China's financing in
CRO/ CDMO has doubled from 2020. The
CAGR over the past five years was 27%.
As firms come to rely more
heavily on outsourcing
companies for more
advanced work, they will
need to invest, expand and
upgrade their current
premises and facilities to
meet these needs.
VC Investment by Sector
Services
14%
Diagnostic
14%
US$ billion
China Life Sciences - 2022
China's life sciences investment value
increased by 55% in 2021, of which
PE/VC funds grew by nearly 90%.
120
100
80
60
40
8622
Drug
36%
20
China Life sciences Investment Activity
2019
2020
12021
ihealth
15%
Device
21%
New VC/PE funds
VC/PE
investment
M&A
IPO
Source: Savills Research using ChinaBio dataView entire presentation